Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Identifieur interne : 000054 ( France/Analysis ); précédent : 000053; suivant : 000055Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
Auteurs : Amandine Legat [Suisse] ; Hélène Maby-El Hajjami [Suisse] ; Petra Baumgaertner [Suisse] ; Laurène Cagnon [Suisse] ; Samia Abed Maillard [Suisse] ; Christine Geldhof [Suisse] ; Emanuela M. Iancu [Suisse] ; Luc Lebon [Suisse] ; Philippe Guillaume [Suisse] ; Danijel Dojcinovic [Suisse] ; Olivier Michielin [Suisse] ; Emanuela Romano [Suisse] ; Grégoire Berthod [Suisse] ; Donata Rimoldi [Suisse] ; Frédéric Triebel [France] ; Immanuel Luescher [Suisse] ; Nathalie Rufer [Suisse] ; Daniel E. Speiser [Suisse]Source :
- Clinical cancer research : an official journal of the American Association for Cancer Research [ 1078-0432 ] ; 2016.
Descripteurs français
- KwdFr :
- Antigène MART-1 (immunologie), Antigènes CD (), Antigènes CD (immunologie), Antigènes néoplasiques (immunologie), Association thérapeutique, Femelle, Humains, Lymphocytes T CD4+ (immunologie), Lymphocytes T CD4+ (métabolisme), Lymphocytes T CD8+ (immunologie), Lymphocytes T CD8+ (métabolisme), Marqueurs biologiques, Mâle, Mélanome (), Mélanome (anatomopathologie), Mélanome (immunologie), Numération des lymphocytes, Peptides (immunologie), Résultat thérapeutique, Vaccination, Vaccins anticancéreux (administration et posologie), Vaccins anticancéreux (effets indésirables), Vaccins anticancéreux (immunologie).
- MESH :
- administration et posologie : Vaccins anticancéreux.
- anatomopathologie : Mélanome.
- effets indésirables : Vaccins anticancéreux.
- immunologie : Antigène MART-1, Antigènes CD, Antigènes néoplasiques, Lymphocytes T CD4+, Lymphocytes T CD8+, Mélanome, Peptides, Vaccins anticancéreux.
- métabolisme : Lymphocytes T CD4+, Lymphocytes T CD8+.
- Antigènes CD, Association thérapeutique, Femelle, Humains, Marqueurs biologiques, Mâle, Mélanome, Numération des lymphocytes, Résultat thérapeutique, Vaccination.
English descriptors
- KwdEn :
- Antigens, CD (chemistry), Antigens, CD (immunology), Antigens, Neoplasm (immunology), Biomarkers, CD4-Positive T-Lymphocytes (immunology), CD4-Positive T-Lymphocytes (metabolism), CD8-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (metabolism), Cancer Vaccines (administration & dosage), Cancer Vaccines (adverse effects), Cancer Vaccines (immunology), Combined Modality Therapy, Female, Humans, Lymphocyte Count, MART-1 Antigen (immunology), Male, Melanoma (immunology), Melanoma (pathology), Melanoma (therapy), Peptides (immunology), Treatment Outcome, Vaccination.
- MESH :
- chemical , administration & dosage : Cancer Vaccines.
- chemical , adverse effects : Cancer Vaccines.
- chemical , chemistry : Antigens, CD.
- chemical , immunology : Antigens, CD, Antigens, Neoplasm, Cancer Vaccines, MART-1 Antigen, Peptides.
- chemical : Biomarkers.
- immunology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Melanoma.
- metabolism : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes.
- pathology : Melanoma.
- therapy : Melanoma.
- Combined Modality Therapy, Female, Humans, Lymphocyte Count, Male, Treatment Outcome, Vaccination.
Abstract
Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synthetic peptides derived from tumor-associated antigens (four short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary endpoints were safety and T-cell responses.
DOI: 10.1158/1078-0432.CCR-15-1212
PubMed: 26500235
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001413
- to stream PubMed, to step Curation: 001413
- to stream PubMed, to step Checkpoint: 000E53
- to stream Ncbi, to step Merge: 001326
- to stream Ncbi, to step Curation: 001326
- to stream Ncbi, to step Checkpoint: 001326
- to stream Main, to step Merge: 000F67
- to stream Main, to step Curation: 000F64
- to stream Main, to step Exploration: 000F64
- to stream France, to step Extraction: 000054
Links to Exploration step
pubmed:26500235Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.</title><author><name sortKey="Legat, Amandine" sort="Legat, Amandine" uniqKey="Legat A" first="Amandine" last="Legat">Amandine Legat</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Maby El Hajjami, Helene" sort="Maby El Hajjami, Helene" uniqKey="Maby El Hajjami H" first="Hélène" last="Maby-El Hajjami">Hélène Maby-El Hajjami</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Baumgaertner, Petra" sort="Baumgaertner, Petra" uniqKey="Baumgaertner P" first="Petra" last="Baumgaertner">Petra Baumgaertner</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Cagnon, Laurene" sort="Cagnon, Laurene" uniqKey="Cagnon L" first="Laurène" last="Cagnon">Laurène Cagnon</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Abed Maillard, Samia" sort="Abed Maillard, Samia" uniqKey="Abed Maillard S" first="Samia" last="Abed Maillard">Samia Abed Maillard</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Geldhof, Christine" sort="Geldhof, Christine" uniqKey="Geldhof C" first="Christine" last="Geldhof">Christine Geldhof</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Iancu, Emanuela M" sort="Iancu, Emanuela M" uniqKey="Iancu E" first="Emanuela M" last="Iancu">Emanuela M. Iancu</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Lebon, Luc" sort="Lebon, Luc" uniqKey="Lebon L" first="Luc" last="Lebon">Luc Lebon</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Guillaume, Philippe" sort="Guillaume, Philippe" uniqKey="Guillaume P" first="Philippe" last="Guillaume">Philippe Guillaume</name><affiliation wicri:level="1"><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>TCMetrix, Epalinges</wicri:regionArea><wicri:noRegion>Epalinges</wicri:noRegion></affiliation></author><author><name sortKey="Dojcinovic, Danijel" sort="Dojcinovic, Danijel" uniqKey="Dojcinovic D" first="Danijel" last="Dojcinovic">Danijel Dojcinovic</name><affiliation wicri:level="1"><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>TCMetrix, Epalinges</wicri:regionArea><wicri:noRegion>Epalinges</wicri:noRegion></affiliation></author><author><name sortKey="Michielin, Olivier" sort="Michielin, Olivier" uniqKey="Michielin O" first="Olivier" last="Michielin">Olivier Michielin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Romano, Emanuela" sort="Romano, Emanuela" uniqKey="Romano E" first="Emanuela" last="Romano">Emanuela Romano</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Berthod, Gregoire" sort="Berthod, Gregoire" uniqKey="Berthod G" first="Grégoire" last="Berthod">Grégoire Berthod</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Rimoldi, Donata" sort="Rimoldi, Donata" uniqKey="Rimoldi D" first="Donata" last="Rimoldi">Donata Rimoldi</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Triebel, Frederic" sort="Triebel, Frederic" uniqKey="Triebel F" first="Frédéric" last="Triebel">Frédéric Triebel</name><affiliation wicri:level="3"><nlm:affiliation>Immutep, SA, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Immutep, SA, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Luescher, Immanuel" sort="Luescher, Immanuel" uniqKey="Luescher I" first="Immanuel" last="Luescher">Immanuel Luescher</name><affiliation wicri:level="1"><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>TCMetrix, Epalinges</wicri:regionArea><wicri:noRegion>Epalinges</wicri:noRegion></affiliation></author><author><name sortKey="Rufer, Nathalie" sort="Rufer, Nathalie" uniqKey="Rufer N" first="Nathalie" last="Rufer">Nathalie Rufer</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E" last="Speiser">Daniel E. Speiser</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland. doc@dspeiser.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26500235</idno><idno type="pmid">26500235</idno><idno type="doi">10.1158/1078-0432.CCR-15-1212</idno><idno type="wicri:Area/PubMed/Corpus">001413</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001413</idno><idno type="wicri:Area/PubMed/Curation">001413</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001413</idno><idno type="wicri:Area/PubMed/Checkpoint">000E53</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E53</idno><idno type="wicri:Area/Ncbi/Merge">001326</idno><idno type="wicri:Area/Ncbi/Curation">001326</idno><idno type="wicri:Area/Ncbi/Checkpoint">001326</idno><idno type="wicri:doubleKey">1078-0432:2016:Legat A:vaccination:with:lag</idno><idno type="wicri:Area/Main/Merge">000F67</idno><idno type="wicri:Area/Main/Curation">000F64</idno><idno type="wicri:Area/Main/Exploration">000F64</idno><idno type="wicri:Area/France/Extraction">000054</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.</title><author><name sortKey="Legat, Amandine" sort="Legat, Amandine" uniqKey="Legat A" first="Amandine" last="Legat">Amandine Legat</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Maby El Hajjami, Helene" sort="Maby El Hajjami, Helene" uniqKey="Maby El Hajjami H" first="Hélène" last="Maby-El Hajjami">Hélène Maby-El Hajjami</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Baumgaertner, Petra" sort="Baumgaertner, Petra" uniqKey="Baumgaertner P" first="Petra" last="Baumgaertner">Petra Baumgaertner</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Cagnon, Laurene" sort="Cagnon, Laurene" uniqKey="Cagnon L" first="Laurène" last="Cagnon">Laurène Cagnon</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Abed Maillard, Samia" sort="Abed Maillard, Samia" uniqKey="Abed Maillard S" first="Samia" last="Abed Maillard">Samia Abed Maillard</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Geldhof, Christine" sort="Geldhof, Christine" uniqKey="Geldhof C" first="Christine" last="Geldhof">Christine Geldhof</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Iancu, Emanuela M" sort="Iancu, Emanuela M" uniqKey="Iancu E" first="Emanuela M" last="Iancu">Emanuela M. Iancu</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Lebon, Luc" sort="Lebon, Luc" uniqKey="Lebon L" first="Luc" last="Lebon">Luc Lebon</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Guillaume, Philippe" sort="Guillaume, Philippe" uniqKey="Guillaume P" first="Philippe" last="Guillaume">Philippe Guillaume</name><affiliation wicri:level="1"><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>TCMetrix, Epalinges</wicri:regionArea><wicri:noRegion>Epalinges</wicri:noRegion></affiliation></author><author><name sortKey="Dojcinovic, Danijel" sort="Dojcinovic, Danijel" uniqKey="Dojcinovic D" first="Danijel" last="Dojcinovic">Danijel Dojcinovic</name><affiliation wicri:level="1"><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>TCMetrix, Epalinges</wicri:regionArea><wicri:noRegion>Epalinges</wicri:noRegion></affiliation></author><author><name sortKey="Michielin, Olivier" sort="Michielin, Olivier" uniqKey="Michielin O" first="Olivier" last="Michielin">Olivier Michielin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Romano, Emanuela" sort="Romano, Emanuela" uniqKey="Romano E" first="Emanuela" last="Romano">Emanuela Romano</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Berthod, Gregoire" sort="Berthod, Gregoire" uniqKey="Berthod G" first="Grégoire" last="Berthod">Grégoire Berthod</name><affiliation wicri:level="3"><nlm:affiliation>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Rimoldi, Donata" sort="Rimoldi, Donata" uniqKey="Rimoldi D" first="Donata" last="Rimoldi">Donata Rimoldi</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Triebel, Frederic" sort="Triebel, Frederic" uniqKey="Triebel F" first="Frédéric" last="Triebel">Frédéric Triebel</name><affiliation wicri:level="3"><nlm:affiliation>Immutep, SA, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Immutep, SA, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Luescher, Immanuel" sort="Luescher, Immanuel" uniqKey="Luescher I" first="Immanuel" last="Luescher">Immanuel Luescher</name><affiliation wicri:level="1"><nlm:affiliation>TCMetrix, Epalinges, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>TCMetrix, Epalinges</wicri:regionArea><wicri:noRegion>Epalinges</wicri:noRegion></affiliation></author><author><name sortKey="Rufer, Nathalie" sort="Rufer, Nathalie" uniqKey="Rufer N" first="Nathalie" last="Rufer">Nathalie Rufer</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author><author><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E" last="Speiser">Daniel E. Speiser</name><affiliation wicri:level="3"><nlm:affiliation>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne, Switzerland. doc@dspeiser.ch.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Ludwig Cancer Research Center, University of Lausanne, Lausanne, Switzerland. Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Lausanne</wicri:regionArea><placeName><settlement type="city">Lausanne</settlement><region nuts="3" type="region">Canton de Vaud</region></placeName></affiliation></author></analytic><series><title level="j">Clinical cancer research : an official journal of the American Association for Cancer Research</title><idno type="ISSN">1078-0432</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigens, CD (chemistry)</term><term>Antigens, CD (immunology)</term><term>Antigens, Neoplasm (immunology)</term><term>Biomarkers</term><term>CD4-Positive T-Lymphocytes (immunology)</term><term>CD4-Positive T-Lymphocytes (metabolism)</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>CD8-Positive T-Lymphocytes (metabolism)</term><term>Cancer Vaccines (administration & dosage)</term><term>Cancer Vaccines (adverse effects)</term><term>Cancer Vaccines (immunology)</term><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Lymphocyte Count</term><term>MART-1 Antigen (immunology)</term><term>Male</term><term>Melanoma (immunology)</term><term>Melanoma (pathology)</term><term>Melanoma (therapy)</term><term>Peptides (immunology)</term><term>Treatment Outcome</term><term>Vaccination</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antigène MART-1 (immunologie)</term><term>Antigènes CD ()</term><term>Antigènes CD (immunologie)</term><term>Antigènes néoplasiques (immunologie)</term><term>Association thérapeutique</term><term>Femelle</term><term>Humains</term><term>Lymphocytes T CD4+ (immunologie)</term><term>Lymphocytes T CD4+ (métabolisme)</term><term>Lymphocytes T CD8+ (immunologie)</term><term>Lymphocytes T CD8+ (métabolisme)</term><term>Marqueurs biologiques</term><term>Mâle</term><term>Mélanome ()</term><term>Mélanome (anatomopathologie)</term><term>Mélanome (immunologie)</term><term>Numération des lymphocytes</term><term>Peptides (immunologie)</term><term>Résultat thérapeutique</term><term>Vaccination</term><term>Vaccins anticancéreux (administration et posologie)</term><term>Vaccins anticancéreux (effets indésirables)</term><term>Vaccins anticancéreux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Cancer Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antigens, CD</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, CD</term><term>Antigens, Neoplasm</term><term>Cancer Vaccines</term><term>MART-1 Antigen</term><term>Peptides</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Biomarkers</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins anticancéreux</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Mélanome</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins anticancéreux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigène MART-1</term><term>Antigènes CD</term><term>Antigènes néoplasiques</term><term>Lymphocytes T CD4+</term><term>Lymphocytes T CD8+</term><term>Mélanome</term><term>Peptides</term><term>Vaccins anticancéreux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term><term>CD8-Positive T-Lymphocytes</term><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term><term>CD8-Positive T-Lymphocytes</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Lymphocytes T CD4+</term><term>Lymphocytes T CD8+</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Melanoma</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Lymphocyte Count</term><term>Male</term><term>Treatment Outcome</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antigènes CD</term><term>Association thérapeutique</term><term>Femelle</term><term>Humains</term><term>Marqueurs biologiques</term><term>Mâle</term><term>Mélanome</term><term>Numération des lymphocytes</term><term>Résultat thérapeutique</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synthetic peptides derived from tumor-associated antigens (four short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary endpoints were safety and T-cell responses.</div></front></TEI><affiliations><list><country><li>France</li><li>Suisse</li></country><region><li>Canton de Vaud</li></region><settlement><li>Lausanne</li><li>Orsay</li></settlement></list><tree><country name="Suisse"><region name="Canton de Vaud"><name sortKey="Legat, Amandine" sort="Legat, Amandine" uniqKey="Legat A" first="Amandine" last="Legat">Amandine Legat</name></region><name sortKey="Abed Maillard, Samia" sort="Abed Maillard, Samia" uniqKey="Abed Maillard S" first="Samia" last="Abed Maillard">Samia Abed Maillard</name><name sortKey="Baumgaertner, Petra" sort="Baumgaertner, Petra" uniqKey="Baumgaertner P" first="Petra" last="Baumgaertner">Petra Baumgaertner</name><name sortKey="Berthod, Gregoire" sort="Berthod, Gregoire" uniqKey="Berthod G" first="Grégoire" last="Berthod">Grégoire Berthod</name><name sortKey="Cagnon, Laurene" sort="Cagnon, Laurene" uniqKey="Cagnon L" first="Laurène" last="Cagnon">Laurène Cagnon</name><name sortKey="Dojcinovic, Danijel" sort="Dojcinovic, Danijel" uniqKey="Dojcinovic D" first="Danijel" last="Dojcinovic">Danijel Dojcinovic</name><name sortKey="Geldhof, Christine" sort="Geldhof, Christine" uniqKey="Geldhof C" first="Christine" last="Geldhof">Christine Geldhof</name><name sortKey="Guillaume, Philippe" sort="Guillaume, Philippe" uniqKey="Guillaume P" first="Philippe" last="Guillaume">Philippe Guillaume</name><name sortKey="Iancu, Emanuela M" sort="Iancu, Emanuela M" uniqKey="Iancu E" first="Emanuela M" last="Iancu">Emanuela M. Iancu</name><name sortKey="Lebon, Luc" sort="Lebon, Luc" uniqKey="Lebon L" first="Luc" last="Lebon">Luc Lebon</name><name sortKey="Luescher, Immanuel" sort="Luescher, Immanuel" uniqKey="Luescher I" first="Immanuel" last="Luescher">Immanuel Luescher</name><name sortKey="Maby El Hajjami, Helene" sort="Maby El Hajjami, Helene" uniqKey="Maby El Hajjami H" first="Hélène" last="Maby-El Hajjami">Hélène Maby-El Hajjami</name><name sortKey="Michielin, Olivier" sort="Michielin, Olivier" uniqKey="Michielin O" first="Olivier" last="Michielin">Olivier Michielin</name><name sortKey="Rimoldi, Donata" sort="Rimoldi, Donata" uniqKey="Rimoldi D" first="Donata" last="Rimoldi">Donata Rimoldi</name><name sortKey="Romano, Emanuela" sort="Romano, Emanuela" uniqKey="Romano E" first="Emanuela" last="Romano">Emanuela Romano</name><name sortKey="Rufer, Nathalie" sort="Rufer, Nathalie" uniqKey="Rufer N" first="Nathalie" last="Rufer">Nathalie Rufer</name><name sortKey="Speiser, Daniel E" sort="Speiser, Daniel E" uniqKey="Speiser D" first="Daniel E" last="Speiser">Daniel E. Speiser</name></country><country name="France"><noRegion><name sortKey="Triebel, Frederic" sort="Triebel, Frederic" uniqKey="Triebel F" first="Frédéric" last="Triebel">Frédéric Triebel</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000054 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000054 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= France
|étape= Analysis
|type= RBID
|clé= pubmed:26500235
|texte= Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i -Sk "pubmed:26500235" \
| HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |